Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Roche

Genentech Builds Case For Rituxan In Pemphigus With Comparator Study Data

Genentech reports that Rituxan yields better results over 52 weeks in pemphigus patients than off-label use of CellCept. Principia, meanwhile, unveils positive Phase II data for its pemphigus candidate.

Clinical Trials Rare Diseases

Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies

Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.
Commercial Companies

EU Accelerated Assessment Tracker

Roche has secured accelerated assessment at the European Medicines Agency for its new immunosuppressant, satralizumab. The outcomes of five other fast-track requests that companies have made for their planned marketing authorization applications are still unknown.

Europe European Performance Tracker

GSK's Hal Barron On R&D Progress At Two-Year Mark

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

C-Suite Speaks Research and Development Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register